# Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT01379807** · PHASE2 · UNKNOWN · sponsor: **Grupo Gallego de Investigaciones Oncologicas** · enrollment: 55 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** panitumumab + docetaxel + cisplatino

## Key facts

- **NCT ID:** NCT01379807
- **Lead sponsor:** Grupo Gallego de Investigaciones Oncologicas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-12
- **Primary completion:** 2014-12
- **Final completion:** 2015-12
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2015-03-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01379807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01379807, "Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01379807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*